Amgen CEO Bob Bradway highlighted that the company’s weight-loss portfolio is entering a high-growth phase, with the flagship GLP-1 therapy generating over 320 million dollars in global sales during Q4 2025. He noted that new patient starts increased by 45% year-over-year in the fourth quarter, driven by expanded payer coverage across 12 major U.S. insurers. Management forecasts that weight-loss treatments will contribute roughly 15% of total revenue by the end of 2026, up from 5% in 2024, underscoring the segment’s accelerating commercial momentum.

In a mid-stage extension study involving 200 obese participants, Amgen’s experimental obesity drug MariTide helped maintain 85% of initial weight loss over 24 weeks after the primary treatment period. A separate diabetes cohort of 120 patients recorded an average HbA1c reduction of 1.3 percentage points alongside a mean weight loss of 6.5% body weight. These results, to be presented at the upcoming healthcare conference, strengthen the case for a potential late-stage trial initiation by year-end and position MariTide as a key pipeline asset with peak annual sales potential estimated at 3 billion dollars.

Amgen has entered a research collaboration with telehealth provider Ro to investigate barriers to obesity treatment and GLP-1 access across the United States. The study will enroll 1,500 patients and survey 300 primary-care and obesity-specialist clinicians across 100 sites. Initial findings, expected in Q3 2026, will quantify coverage denials, out-of-pocket cost burdens and referral delays. Amgen plans to leverage these insights to inform payer negotiations and support targeted patient assistance programs, potentially reducing time to therapy initiation by up to 30%.

At the 44th Annual J.P. Morgan Healthcare Conference, management described 2026 as a "springboard year," with 20 Phase II and III readouts scheduled across cardiovascular, oncology, inflammation and rare disease indications. Highlights include a Phase III readout for a novel PCSK9 inhibitor in familial hypercholesterolemia enrolling over 500 patients, and mid-stage data for an investigational gene therapy targeting spinal muscular atrophy in a 60-patient cohort. Amgen’s branded biosimilars, which delivered 1.8 billion dollars in sales in 2025, will also benefit from several patent expirations, reinforcing the company’s diversified growth model.